showing that TPN may lead to intestinal dysfunction, including villus atrophy and disruption of epithelial barrier function, both of which may contribute to an associated increase in clinical complications such as gut-derived sepsis or parenteral nutrition associated liver disease (PNALD). 2, 3 Therefore, effective strategies for maintaining intestinal homeostasis and preventing intestinal dysbiosis from various pathologic stimuli are crucially needed. Recently, one of our previous studies indicated that lipid emulsion, a key component of TPN solution, could suppress the intestinal expression of P-glycoprotein (P-gp) in vitro, leading to increased permeability of lipopolysaccharide through transcellular route. 4 However, it still remains elusive whether P-gp is downregulated by TPN in vivo, as well as its potential correlation with TPN-induced intestinal barrier dysfunction. P-glycoprotein (P-gp, 170 kDa) is a phosphorylated and glycosylated plasma membrane protein which belongs to the ATP binding cassette super family. 5 In gastrointestinal tract, it is found in high concentrations on the apical surfaces of superficial epithelial cells of the ileum and proximal colon. 6 In addition to its efflux function that removes drugs from the cytoplasm, emerging evidence also indicated that intestinal P-gp may act as a natural defense mechanism against pathogenic microorganisms. 7-10 More importantly, however, Andrew reported that loss function of P-gp led to significantly increased bacteria attachment to intestinal epithelial cells in vitro, 11 which aroused our great interest to ask whether downregulation of P-gp under TPN may facilitate the attachment of pathogenic microorganisms to epithelial cells and thereby drive the disruption of intestinal barrier function.
A common finding in the context of TPN, including animal models (mouse, rat, and piglet), [12] [13] [14] human neonate babies (most of them premature), 15 and adult patients with intestinal failure, 16, 17 involves changed gut microbiota. Most of them indicated a remarkable shift from Firmicutes to Proteobactoria and Bacteroidetes, that is, Salmonella, Proteus, Escherichia, Bacteroides, which are often associated with clinical infections, potentially indicating the development of a pathological state within the intestinal microbial community. Conceivably, it is still quite difficult to fully address the role of all these potential pathogens in the development of intestinal barrier dysfunction; however, by using type strains like pathogenic Escherichia coli (E. coli) k88 or nonpathogenic E. coli DH5α, a number of possible mechanisms have been identified, including redistribution of tight junctions, 18 disassembly of microtubules, 19 and inhibition of host defense. 20 Nevertheless, none of them were investigated from the perspective of P-gp.
In this study, by using rat TPN model in vivo and Caco-2 cell model in vitro, we hypothesize that in the context of TPN early downregulation of P-gp may facilitate bacterial attachment to IECS, and thereby trigger the degradation of tight junctions, leading to consequent disruption of barrier function.
| MATERIALS AND METHODS

| TPN rat model
Sprague-Dawley male, specific-pathogen-free 4-to 5-week old rats (Shanghai Laboratory Animal Center, Shanghai, China) were maintained under 25°C ± 0.5°C and 40%-60% relative humidity. Rats were initially fed ad libitum with standard chow (Xietong Organism, Jiangsu, China) and sterile water. After 1-week acclimatization, rats were randomized to sham or TPN group (n = 5-6/group). Surgery procedure and composition of TPN solution was identical to that previously described. 21 The TPN group received TPN delivery (400 kcal/kg/d) continuously for 7 days but was allowed water ad libitum; the sham group received exactly same process and infused with saline and fed with standard chow ad libitum. All animals were sacrificed at either 3 or 7 days post-surgery using CO 2 . The studies were approved by Xin Hua Hospital Animal Use Committee.
| Adenovirus-mediated overexpression of
P-gp in vivo
For overexpression of P-gp in vivo, the adenovirus were designed and packaged by Shanghai Sunbio Medical Biotechnology (vector: pAV.mCMV,RFP; RefSeq: Abcb1/ NM_133401). The animals were intravenously injected with adenovirus containing either vector-RFP or P-gp-RFP at 1.0 × 10 10 PFU/kg 3 days before TPN administration.
| Sample collection
Ileum and colon were isolated about 20 cm proximal to the ileocecal valve, and 5 cm distal to the ileocecal valve, respectively.
| Simultaneous determination of intestinal barrier function and P-gp function in vivo
Intestinal barrier function as well as P-gp function was evaluated by using in situ loop method as described previously with slight modification. 22 Briefly, rats were placed on a heating pad to maintain the body temperature at 37°C. The abdomen was opened by a midline longitudinal incision, and a 7-cm ileal segment was isolated and cannulated at both ends with plastic tubing. The segment was rinsed with natural saline, and then Krebs-Henseleit bicarbonate buffer (KHBB, pH 7.4) solution containing Rhodamine 123 (Rho123, 1 μg/mL) and TRITC-Dextran 4000 (TD4000, 1 mg/mL) was added to the loop at 20 mL/kg. Blood sample was collected from the portal vein until 60 minutes after the administration of Rho123/TD4000. The concentration of Rho123 and TD4000 in serum was measured using a fluorescent spectrophotometer (SpectraMax, CA, USA) at 485/525 nm and 550/580 nm, respectively.
| Examination of E. coli attachment to
IECs in vivo
Examination of E. coli attachment was evaluated by using in situ loop method. The isolation and cannulation of ileal loop was performed as described above. E. coli (DH5α and k88) was labeled with fluorescent syto9 dye according to the manufacturer's instructions (Cat no. S34854, thermo, USA). KHBB solution containing syto9-labeled E. coli (2.0 × 10 8 CFU/mL) was added to the loop at 20 mL/kg. Following 60-minutes incubation, ileal segment was removed and rinsed with cold saline, and then cut into several small segments (0.5-1 cm) for the preparation of frozen slices. For inhibition study, P-gp inhibitors Verapamil (50 μM) or PSC833 (2 μM) were co-incubated with the labeled E. coli. Attachment of E. coli to IECs was visualized using Leica DMI6000B fluorescence microscopy with LAS AF LITE image processing software (Leica, Germany). Areas of infection (AOI) in each slice were marked, in which signal intensity (gray values) was determined and exported as histogram, so that the severity of E. coli infection could be semi-quantitatively analyzed. At least 50 AOIs in each group were examined, and overall results were statistically analyzed by comparing mean gray values in each group.
| Immunofluorescence (IF) staining
For in vivo experiments, paraffin-embedded tissue sections (5 μm) were stained using standard IF procedures. Briefly, sections were blocked with 5% BSA for 1 hour at room temperature, followed by incubation with a primary antibody against P-gp (1:500) at 4°C overnight. The signal was visualized with Alexa Fluor 488-conjugated secondary antibody followed by counterstaining with 4′,6-diamidino-2-phenylindole (DAPI). For in vitro experiments, Caco-2 cells were fixed in 4% formaldehyde at room temperature for 15 minutes, and permeabilized with 0.2% TritonX-100 in PBS for 15 minutes. After blocking (5% BSA, 1 hour), the cells were incubated with primary antibodies against either P-gp (1:500) or Occludin (1:400) at 4°C overnight, followed by incubation with Alexa Fluor 488-or 594-conjugated secondary antibodies for 1 hour at room temperature. Images were visualized using Leica DMI6000B fluorescence microscopy with LAS AF LITE image processing software (Leica, Germany).
| Cell culture and reagents
Caco-2 cells (ATCC, USA) were cultured in DMEM containing 10% FBS under standard cell culture conditions as described previously. 23 Cell culture reagents were obtained from Thermo (Shanghai, China). Mouse anti-Occludin and GAPDH were purchased from Santa Cruz (Shanghai, China). Mouse anti-E-cadherin was purchased from BD (Shanghai, China). Rabbit anti-P-gp was purchased from Cell Signaling Technology (CST, Shanghai, China). Rabbit anti-ZO1 was purchased from Abcam (Shanghai, China). All other chemicals were purchased from Sigma (Shanghai, China).
| Bacterial growth and cell treatment
The pathogenic strain of E. coli k88 and the nonpathogenic strain of E. coli DH5α were obtained from BeNa Culture Collection (Beijing, China) and Beyotime Technology (Shanghai, China), respectively. The bacteria were cultured in Luria-Bertani broth at 37°C in a shaking incubator overnight. Enumeration of E. coli was evaluated by OD 600 (0.5 OD = 5 × 10 7 CFU/mL). Long-term co-incubation (2~16 hours) with E. coli and Caco-2 cells was maintained with antibiotics as follows. E. coli k88 treatment: confluent Caco-2 cell monolayers were treated with DMEM (supplemented with penicillin and streptomycin at 500 U/mL and 0.5 mg/ mL, respectively) containing exponentially grown bacteria (k88) at a multiplicity of infection (MOI) of 25:1, 50:1 and 100:1; E. coli DH5α treatment: confluent Caco-2 cell monolayers were treated with DMEM (supplemented with penicillin and streptomycin at 200 U/mL and 0.2 mg/mL, respectively) containing exponentially grown bacteria (DH5α) at a MOI of 25:1, 50:1 and 100:1. For inhibition studies, P-gp inhibitors Verapamil (50 μM) or PSC833 (2 μM) were coincubated with the E. coli. These experimental conditions have been tested in the preliminary studies to exclude the following risks: the impact of using antibiotics on the barrier function of Caco-2 cell monolayers; the impact of E. coli and antibiotics on the viability of Caco-2 cells; the impact of P-gp inhibitors on the growth of the bacteria as well as the viability of Caco-2 cells.
| Determination of intestinal barrier function in vitro
Caco-2 cells were cultured on Transwell inserts (12 mm diameter, 0.4 μm pore size; Corning Costar Co., USA) for 14 days to allow full maturation of the cell monolayer. Intestinal barrier function was determined by measuring transepithelial electrical resistance (TEER) and FITC-Dextran 4000 (FD4000, sigma) permeability. Briefly, 0.5 mL of FD4000 (1 mg/mL in DMEM) was loaded into the apical chamber for 2 hours, and 0.1-mL aliquots were sampled from the basolateral chamber every 0.5 hour. Concentration of FD4000 was determined with a fluorescent spectrophotometer (SpectraMax, CA, USA) at 485/525 nm.
| Examination of E. coli attachment to
Caco-2 cells in vitro
E. coli (DH5α and k88) was labeled with syto9 dye according to the manufacturer's instructions. Following E. coli treatment, extracellular bacteria were removed and the cells were washed with PBS (pH 7.4). Cells were imaged under Leica DMI6000B fluorescence microscopy (Leica, Germany). For quantification, cells were detached and fixed in 75% ethanol for 2 hours, followed by counting with a FACSCanto flow cytometer (Becton Dickinson, USA). At least 10 000 cells were collected for each measurement.
| Quantitative real-time PCR (Q-PCR)
Total RNA was extracted using Trizol (life technology, USA), and cDNA was synthesized with an RNA isolation plus kit (Takara, Japan) according to the manufacturer's protocol. Quantitative real-time PCR and data analysis were performed using PIKO96 (Thermo, Germany). Primers used in this study are listed as follows: rat P-gp: 5′-GACGGGGAACTTAGCACCAA-3′ (forward) and 5′-CCTAGACCCTGTAGCCCCTT-3′ (reverse); rat GAPDH: 5′-AGTGCCAGCCTCGTCTCATA-3′ (forward) and 5′-CTCGTGGTTCACACCCATCA-3′ (reverse); human Occludin: 5′-TTTGTGGGACAAGGAACACA-3′ (forward) and 5′-GCAGGTGCTCTTTTTGAAGG-3′ (reverse); human GAPDH: 5′-TATTGTTGCCATCAATGACCC-3′ (forward) and 5′-ACTCCACGACGTACTCAGC-3′ (reverse).
| Western blot analysis
For in vivo studies, intestinal mucosal content was prepared using a modification of Grossmann's technique as described previously. Briefly, the epithelial cell layer was scraped from the submucosa, followed by homogenation in a 2 mL tube using MagNa Lyser (Roche, Penzberg, Germany). For in vitro studies, cells were harvested and lyzed on ice for 30 minutes in 100 μL of RIPA buffer. Following centrifugation at 10 000 g for 10 minutes, the resulting supernatant was collected, and protein concentrations were determined using a BCA protein assay kit (Thermo, USA). The immunoblots were visualized with a ChemiDoc XRS + system (Bio-Rad, Hercules, CA, USA), and band density was measured with Image J software (v1.51).
| Analysis of nascent protein synthesis
Nascent Occludin was detected by L-azidohomoalanine (AHA)-labeling Click-iT protein analysis detection kit according to the manufacturer's protocol (Cat no. C10102 and C10276, Thermo, USA).
| Protein stability assay
Cells were treated with cycloheximide (CHX, 0.1 mg/mL) for 0, 4, 8, 12, and 16 hours. The protein abundance of Occludin at 0 hours time point was set as 100% and thereafter the percentage of normalized Occludin protein levels vs time was plotted.
| Matrix metalloprotease 2/9 (MMP2/9) activity assay
Following treatment, the conditioned media were collected, and changes in MMP2/9 activity were determined by using the AnaSpec SensoLyte 520 MMP2/9 Assay Kit (AnaSpec, San Jose, CA) according to the manufacturer's instructions.
| Statistical analysis
Data are expressed as the mean ± the standard deviation (SD). Comparisons between two groups were assessed using a Student's two-tailed t test, and comparisons between multiple groups were assessed using ANOVA followed by the Newman-Keuls post hoc test. Statistical significance was assumed when P < .05.
| RESULTS
| TPN treatment induced early downregulation of P-gp and subsequent disruption of epithelial barrier function
As shown in Figure 1A , TPN administration substantially induced time-dependent decrease in P-gp expression in both ileum and colon. Note that downregulation of P-gp was already evident at 3 days post-TPN administration. Consistently, P-gp mRNA levels were time-dependently downregulated by TPN treatment in both ileum and colon ( Figure 1B) . Anatomically, however, since small bowel exhibits more pathological damages during TPN administration (eg, small bowel bacterial overgrowth), further in vivo experiments were fundamentally performed in ileal tissues. Since luminal Rho 123 is specifically exported by P-gp, increased serum Rho 123 may serve as a biomarker for suppressed P-gp function. As shown in Figure 1C , simultaneous determination of Rho 123 and TD 4000 revealed that suppression of P-gp function was already evident at 3 days post-TPN administration (2.1-fold increase in Rhodamine 123 permeability, P < .01) while disruption of epithelial barrier function was only evident at 7 days post-TPN administration (2.5-fold increase in TD 4000 permeability, P < .05). Consistently, the results of western blot analysis ( Figure 1D ,E) consolidated that the expression of P-gp in ileum mucosa was significantly downregulated at 3 days post-TPN administration (decrease to 55%), while downregulation of tight junction proteins including ZO-1, E-cadherin, and Occludin were only evident at 7 days posttreatment (decrease to about 51%, 39%, and 46%, respectively). Collectively, these results indicated that TPN induced early downregulation of P-gp (3 day) and subsequent downregulation of tight junction proteins (7 day).
| Suppression of p-gp function facilitated
E. coli attachment to IECs in vivo
As shown in Figure 2A ,B, syto9-labeled E. coli k88 and DH5α only exhibited weak signal on the surface of the F I G U R E 1 TPN treatment induced early downregulation of P-gp and subsequent disruption of epithelial barrier function. A, Representative staining of P-gp (green) in ileum and colon. Rats were maintained on TPN for 1-7 day as described in Materials and methods. Note timedependent decline in P-gp expression by TPN treatment. Scale bar = 100 μm. B, P-gp mRNA levels. Rats were treated as described in (A). Data are presented as means ± SD. **P < .01 compared with sham (n = 5 to 6/group). C, P-gp function and epithelial barrier function. P-gp function (left) and epithelial barrier function (right) was simultaneously determined in ileal loop. *P < .05 **P < .01 compared with sham (n = 5 to 6/ group). D, Representative immunoblots of P-gp and tight junction proteins. E, Band intensity of the immunoblots shown in (D). Relative fold was normalized to sham. Data are presented as means ± SD. *P < .05, **P < .01 compared with sham (n =5 to 6/group) villus, suggestive of weak attachment to the IECs in sham rats. In the TPN-3day rats, however, the signal intensity was significantly increased, suggestive of strong attachment of E. coli to the IECs in TPN rats ( Figure 2C,D) . As 3-day TPN administration has led to remarkable suppression of P-gp function as described above, we further examined if F I G U R E 2 Suppression of p-gp function facilitated E. coli attachment to IECs in vivo. A-D, Representative staining and semi-quantitative evaluation of E. coli attachment (DH5α/k88) to IECs in TPN rats. Rats were maintained on TPN for 3 days. Infected cells were labeled green, and areas of infected cells (AOI) were marked. The intensity of syto9 (channel 2) in each AOI was semi-quantitatively determined using histogram analysis (gray vales vs counts). E-G, Representative staining and semi-quantitative evaluation of E. coli (k88) attachment to IECs in the rats with impaired p-gp function. P-gp function was inhibited by either Verapamil or PSC833 as described above. H, Negative control. I, Global analysis of the E. coli attachment to IECs. Mean gray values in 50+ AOIs in each group were statistically analyzed. Data are presented as means ± SD. ***P < .001. Scale bar = 100 μm. Three experiments were performed that showed similar results artificial inhibition of P-gp function may facilitate E. coli attachment to the IECs in vivo. As shown in Figure 2E ,G, the signal of E. coli k88 could be hardly detected in control rats (similar to that in sham rats, Figure 2E) ; however, the signal intensity was significantly increased when the P-gp function was specifically inhibited by using either Verapamil ( Figure 2F ) or PSC833 ( Figure 2G ). No signal can be detected in negative control using unlabeled E. coli k88 ( Figure 2H ). For semi-quantitative comparison, global analysis using mean gray values in each histogram revealed that the attachment of E. coli k88 and DH5α in 3-day TPN group exhibited 3.4-fold increase (P < .001 compared to sham group) and 3.2-fold increase (P < .001 compared to sham group), respectively; and the attachment of E. coli k88 in Verapamil group and in PSC833 group exhibited 4.8-fold increase (P < .001 compared to control group) and 4.3-fold increase (P < .001 compared to control group), respectively. Taken together, these findings suggest that 3-day TPN administration may facilitate the attachment of E. coli to IECs through the suppression of P-gp function in vivo.
| Suppression of p-gp function induced disruption of epithelial barrier function by facilitating E. coli attachment to IECs in vitro
As shown in Figure 3A , intestinal barrier function was dosedependently disrupted by E. coli k88 exposure in vitro, characterized by decreased TEER (a) as well as increased FITC-Dextran permeability (b). Notably, however, suppression of P-gp function significantly aggravated the effect of E. coli exposure, in particular at the MOI = 50. Moreover , as shown in Figure 3B , despite no significant impact observed in the cells exposed to E. coli DH5α at MOI = 25-100 under normal condition (control), suppression of P-gp function by using either Verapamil or PSC833 led to significantly impaired barrier function in the cells exposed to E. coli DH5α at MOI = 100, characterized by about 30% decrease in TEER (a) as well as 2.2-fold increase in FITC-Dextran permeability (b). As the impact of P-gp suppression on E. coli-induced barrier dysfunction was evident in the treatment with E. coli k88 at MOI = 50 and E. coli DH5α at MOI = 100, these conditions were used in the subsequent experiments. We filtered these bacteria to examine whether E. coli-induced disruption of barrier function was attributed to either physical attachment or the soluble toxins released. As shown in Figure 3C , the effect of E. coli k88 and DH5α was completely abolished by filtration, suggesting that physical attachment instead of toxins should be the key of E. coliinduced barrier dysfunction, as well as the key step facilitated by P-gp suppression. Moreover, Figure 3D indicated that the attachment of Syto9-labeled E. coli k88 as well as DH5α to Caco-2 cells was significantly increased by P-gp suppression (in both Verapamil group and PSC833 group). Consistently, the results of flow cytometery revealed that the proportion of E. coli-infected cells was dramatically increased by P-gp suppression: the proportion of DH5α positive cells in control group, Verapamil group and PSC833 group was 52.8%, 80.5%, and 77.3%, respectively; the proportion of k88 positive cells in control group, Verapamil group and PSC833 group was 66.7%, 85.2%, and 88.8%, respectively ( Figure  3E ). Collectively, these results indicated that suppression of p-gp function may induce disruption of epithelial barrier function by facilitating E. coli attachment to IECs in vitro.
| Occludin was downregulated by E. coli challenge under P-gp suppression
As shown in Figure 4A , in the cells exposed to DH5α, neither DH5α alone nor Verapamil alone affected the expression of ZO-1, E-cadherin, Occludin, and Claudin-1. However, treatment with DH5α + Verapamil induced significant decrease in the expression of Occludin. Likewise, in the cells exposed to k88, Occludin was downregulated with the treatment of k88, and was dramatically aggravated by P-gp suppression. Taken together, these findings suggest that Occludin may serve as the key component of tight junctions which is significantly affected by E. coli challenge under P-gp suppression. Consistently, IF study revealed that the expression of Occludin (green) was remarkably decreased only in the DH5α + Verapamil group, while no significant changes were observed in the cells treated with either Verapamil or DH5α alone ( Figure 4B ). Moreover, Figure 4C indicated that 4 hours posttreatment, syto9-labeled k88 (gray) has already exhibited evident invasive tendency to those cells with low P-gp expression compared to those cells with robust P-gp expression (red); however, changes in the expression of Occludin (green) were not evident until 12-16 hours posttreatment, suggesting that (a) downregulation of Occludin is dependent on physical attachment; (b) physical attachment of bacteria to IECs is resulted from P-gp defects. Interestingly, however, no significant changes were observed in Occludin mRNA levels ( Figure 4D ).
| E. coli attachment-induced downregulation of Occludin was mediated by MMP2/9-dependent protein degradation
The mRNA expression of Occludin exhibited no significant changes by DH5α + Verapamil treatment ( Figure 5A ). Moreover, despite total protein levels of Occludin were timedependently decreased, AHA-labeled nascent synthesis of Occludin protein was unchanged ( Figure 5B ), indicating that protein degradation instead of protein translation may be the key. As shown in Figure 5C , under Verapamil (−) condition, no significant differences in the Occludin degradation were observed between DH5a-treated or DH5a-untreated cells, and the half-life of Occludin protein was 13.9 hours and 14.1 hours, respectively. Under Verapamil (+) condition, however, degradation of Occludin was remarkably accelerated in DH5α-treated cells compared to DH5a-untreated cells, and the half-life of Occludin protein was 8.8 hours and 14.8 hours, respectively. Figure 5D indicated that the effect of DH5α+Verapamil on Occludin degradation was significantly abolished by the specific inhibitor to MMP2/9 (SB-3CT). Figure 5E indicated that MMP2/9 activity peaked at 8 hours posttreatment in DH5α + Verapamil group, while no significant changes were observed by either Verapamil or DH5α alone. As for the in vivo part, determination of MMP2/9 activity using ileal tissue lysate revealed that both MMP2 and MMP9 was significantly increased by 3-day TPN treatment ( Figure 5F ), suggesting that 3-day TPN treatment may serve
F I G U R E 3 Suppression of p-gp function induced disruption of epithelial barrier function by facilitating E. coli attachment to IECs in vitro.
A, B, TEER (a) and FITC-Dextran permeability (b). Cells were exposed to either E. coli k88 (A) or DH5α (B) at various MOI (0, 25, 50, and 100) for 16 h. P-gp function was inhibited by either Verapamil or PSC833. Data are presented as means ± SD. *P < 0.05, **P < 0.01 (n =4/group). (C) TEER (a) and FITC-dextran permeability (b). Cells were treated with filtered E. coli /culture media for 16 hours. Data are presented as means ± SD. *P < .05, **P < .01 (n = 4/group). D, Representative images of E. coli attachment to Caco-2 cells. Cells were exposed to either syto9-DH5α or syto9-k88 for 16 hours, and infected cells were labeled green. Scale bar = 100 μm. E, Quantification of E. coli attachment to Caco-2 cells. Cells were treated as described in (D), and the proportion of infected cells was examined by using flow cytometry. Three experiments were performed that showed similar results as a key time-point not only responsible for P-gp downregulation but also for MMPs activation. Taken together, these findings suggested that P-gp suppression may facilitate E. coli attachment, which may subsequently induce downregulation of Occludin by MMP2/9-dependent protein degradation.
| Upregulation of P-gp alleviated
TPN-induced disruption of epithelial barrier function
As shown in Figure 3A , three days after virus administration, fluorescent signal of P-gp-RFP (red) could be already detected on the membrane of IECs along the apical surface of villus. In comparison, the signal of vector-RFP (red) was predominately detectable in the plasma. Notably, TPN-induced disruption of P-gp function and epithelial barrier function were both alleviated by P-gp overexpression. No significant differences were observed between sham and TPN group after P-gp overexpression ( Figure 6B ). More importantly, however, recovery of P-gp function significantly inhibited E. coli attachment in vivo. As shown, roust syto9-k88 signal (green) could be observed in Vector + TPN group, but it was significantly alleviated in P-gp + TPN group. For semi-quantitative comparison, global analysis using mean gray values revealed that the attachment of E. coli k88 was reduced by about 50% after P-gp recovery (Figure 6C,D) . Consistently, the results of western blot consolidated that TPN-induced F I G U R E 4 Occludin was downregulated by E. coli challenge under P-gp suppression. A, Representative blots of tight junction proteins (ZO-1, E-cadherin, Occludin and Claudin-1). Cells were either exposed to DH5α (MOI = 100) or k88 (MOI = 50) for 16 hours, and P-gp function was inhibited by Verapamil. Relative fold of indicated proteins was determined by band intensity. Data are presented as means ± SD. *P < .05, **P < .01 B, Representative images of Occludin staining. Note significant downregulation of Occludin expression (green) in the cells treated with Verapamil + DH5α for 16 hours. Scale bar = 50 μm. C, Representative images of syto9-k88, P-gp and Occludin staining. Attachment of syto9-k88 (gray) as well as the expression of P-gp (red) and Occludin (green) was determined at indicated time. Note time-dependent decrease in Occludin expression (green) in the cells with p-gp defects in combination with k88 infection. Scale bar = 100 μm. Three experiments were performed that showed similar results. D, Occludin mRNA levels. Cells were treated as described in (A). Data are presented as means ± SD downregulation of Occludin was significantly attenuated by P-gp overexpression (Figure 6E,F) . Taken together, these results indicated that TPN-induced disruption of epithelial barrier function could be alleviated by upregulation of P-gp.
| DISCUSSION
Undoubtedly, TPN is the only approach of nutrition support that provides nutrients intravenously for those patients with deprivation of enteral nutrition. It has been estimated that > 375 000 patients rely on TPN each year in the United States according to the United States Healthcare Cost and Utilization Project. 24 However, despite its advantages, evidence is accumulating that TPN, especially long-term TPN, may lead to increasing associated complications like gut-derived infections due in part to disruption of intestinal barrier function. To date, although the underlying mechanisms of intestinal barrier dysfunction have not been fully elucidated, a number of possible contributing factors have been reported in a rodent model of TPN, including aberrant signaling pathways in enterocyte proliferation/ apoptosis, [25] [26] [27] decline in mucosal immunity, 28, 29 dysbiosis, and cascade of inflammatory cytokines leading to disassembly of tight junctions. 30, 31 However, the question is, in addition to all those contributing factors that appear with the development of intestinal barrier dysfunction, whether there exists something else that occurs much earlier and triggers the disruption of barrier function. Recently, intestinal P-gp has been considered as a natural defense mechanism that antagonizes the translocation of harmful substances from the gut to circulation via transcellular route. Neudeck et al's study suggested that P-gp may be involved in host defense against L. monocytogenes, and reduced P-gp on the apical surface of the epithelial cells may constitute a "functional defect" in the intestinal barrier, rendering the host susceptible to bacteria. 8 In addition, Zahida et al demonstrated that P-gp shares the overall architecture with two homodimeric bacterial exporters (Sav1866 and MsbA), showing structural evidence of a crucial role of P-gp in the maintenance of intestinal homeostasis. 32 Taken together with our previous study showing remarkable downregulation of P-gp by lipid emulsion in vitro, this study was thus designed to examine the changes in the expression of intestinal P-gp by TPN in vivo and its underlying significance implicated in the disruption of barrier function.
One of the key findings in this study is the early downregulation of P-gp function. Of note, impaired P-gp function was already evident after 3-day TPN treatment, which was much earlier than disruption of barrier function after 7-day treatment (Figure 1) , indicating a premise that disruption of P-gp function triggers disruption of barrier function. Another intriguing finding is the increased attachment of E. coli to IECs by TPN, which plays a pivotal role in linking P-gp function and barrier function. In the preliminary study, no direct impact of P-gp overexpression could be observed on intestinal barrier function in vitro, neither nor functional suppression with specific inhibitors (data not shown). Interestingly, however, we found that attachment of E. coli was significantly increased in TPN group compared to sham group, and similarly it was also dramatically increased by P-gp suppression compared to control group, showing a possibility that intestinal barrier function may be indirectly regulated by P-gp function through the "bacteria" mediator ( Figure 2) . Indeed, the interaction between host and microbiota is a complex relationship that has not been completely understood, however the reason why E. coli strains (including pathogenic k88 and nonpathogenic DH5α) were used in this study requires comment. First of all, a number of studies using rodent models demonstrated that TPN may lead to Enterobacteriaceae (ie, Salmonella and Escherichia) overgrowth which are often associated with clinical infections 33, 34 ; consistent with the findings in human patients, the composition of microbiota in SBS (short bowel syndrome) patients is remarkably similar to that in TPN animal models. The common feature of the SBS microbiota includes significantly high abundance of Enterobacteriaceae when compared with healthy controls, which positively correlates with PN dependence duration. 35 Given that E. coli is one of the dominant species in the Enterobacteriaceae, it is reasonable to use E. coli strains in further experiments in terms of its representativeness and clinical significance. In addition , both pathogenic k88 and nonpathogenic DH5α were used in this study because they have been proved suitable as type strains to address the role of bacteria in the modulation of intestinal barrier function both in vivo and in vitro. [36] [37] [38] However, unlike most in vitro studies that used k88 and DH5α to address the mechanisms accounting for acute infection (eg, diarrhea), our study was aimed to address their chronic impact on intestinal barrier dysfunction under TPN. Therefore, one of the differences is the use of antibiotics to build a compromised environment, so as to study the long-term interaction between bacteria and host cells (up to 16 hours). Conceivably, compromising with antibiotics is reasonable because hospitalized SBS patients weaning on TPN receive antibiotic treatment clinically. All the experimental conditions (including the dose of antibiotics, MOI and incubation time) used in Figures 3-5 were tested in the preliminary study in order to balance the growth of F I G U R E 5 E. coli attachment-induced downregulation of Occludin was mediated by MMP2/9-dependent protein degradation. A, Occludin mRNA levels. Caco-2 cells were exposed to DH5α (MOI = 100) and Verapamil for indicated time. Data are presented as means ± SD. B, Occludin protein levels. Cells were treated as described in (A). Both total protein of Occludin and newly translated protein of Occludin were examined. Relative fold was determined by band intensity. Data are presented as means ± SD. C, Degradation of Occludin protein. Caco-2 cells were treated with CHX (0.1 mg/mL) for 30 minutes, and then further exposed to Verapamil and DH5α (containing CHX) for the indicated periods. Protein levels were measured by band intensity and calculated as described in methods. D, Occludin protein levels. Cells were pre-treated with SB-3CT (10 μM) for 30 minutes, and then exposed to Verapamil and DH5α as described above. E, MMP2/9 activity in vitro. Cells were exposed to Verapamil and DH5α for indicated time. MMP2/9activity was determined by using activity assay kits. Data are presented as means ± SD. ***, P < .001 compared to control. F, MMP2/9 activity in vivo. Tissue lysate was prepared from ileum, and MMP2/9 activity was normalized to protein content. Data are presented as means ± SD. *P < .05, **, P < .01 compared to control (n = 4-8/group) bacteria as well as host cells. No significant differences in the viability of bacteria and host cells were observed within 16 hours co-incubation. Notably, not only pathogenic k88, but also nonpathogenic DH5α could induce significant disruption of barrier function when P-gp was functionally suppressed in vitro ( Figure  3) , showing the possibility that nonpathogenic bacteria may turn to conditionally pathogenic bacteria under TPN-induced dysbiosis in combination with P-gp suppression in vivo. More importantly, our results also indicated that the impact of P-gp suppression was more likely attributed to the facilitation of bacterial attachment to cell surface instead of intracellular accumulation of toxins, which supported the concept that P-gp may be not only protective of xenotoxic compounds, but also protect from the bacteria themselves getting close enough to initiate F I G U R E 6 Upregulation of P-gp alleviated TPN-induced disruption of epithelial barrier function. A, Representative images of vector/Pgp-RFP. B, P-gp function and epithelial barrier function. P-gp function (left) and epithelial barrier function (right) was simultaneously determined in ileal loop. *P < .05, **P < .01 (n = 4 to 6/group). C, Representative images of E. coli (k88) attachment after P-gp overexpression. Three days after virus administration, the rats were maintained on TPN for another 3 days. Infected cells were labeled green, and areas of infected cells (AOI) were marked. The intensity of syto9 (green) in each AOI was semi-quantitatively determined using histogram analysis as shown in Figure 2 . Scale bar = 100 μm. D, Mean gray values in 40+ AOIs from the rats described in (C) were statistically analyzed. Data are presented as means ± SD. ***P < .001. Three experiments were performed that showed similar results. E, Representative immunoblots of P-gp and Occludin. Duplicates in each group are shown. F, Relative fold normalized to sham-vector. Data are presented as means ± SD. *P < .05, **P < .01 (n = 4 to 6/group) subsequent events that leads to epithelial barrier dysfunction such as disassembly of tight junctions. Nevertheless, there is another possibility needing to be taken into consideration. In addition to the impact of live bacterial attachment, there could be a local concentration effect of bacterial toxins as the bacteria are present right on the surface of the cells and potentially could be excreting toxins there, which would have a localized concentration much higher (given these are live bacteria) than a mixed "conditioned medium" that will have diluted this concentration out, and may be below a threshold needed for an effect. In addition, the mechanism accounting for increased bacterial attachment by P-gp suppression needs further investigation. Presumably, given that some bacterial adhesion factors (polysaccharides) are P-gp substrates, 39 P-gp may be able to recognize these bacterial adhesion factors, and prevent the bacteria from attaching by dislodging these factors from the cell surface. Alternatively, according to Andrew et al's study, 40 since similar effects were observed in various bacterial species with different pathogenicity, it is more likely that endogenous anti-microbial peptides being secreted from these epithelial cells, serve as P-gp substrates that are adversely affecting bacterial attachment. Thus, it is promising to identify these anti-microbial peptides as potential therapeutic targets in future studies.
Occludin is one of the most important and critical components in the structural and functional organization of tight junctions. In this study, we focused on Occludin because it was significantly downregulated by E. coli attachment especially when P-gp was functionally suppressed, which could be observed in both k88 and DH5α treatment ( Figure 4 ). Furthermore, our results also indicated that the mechanism accounting for downregulation of Occludin was attributed to protein degradation instead of translation. In the preliminary study, we excluded the possible involvement of proteasomes-and lysomes-mediated protein degradation, since no significant differences in Occludin expression were observed when specific inhibitors were used. Instead, we tested the possible involvement of matrix metalloproteases (MMPs), because a number of studies recently indicated that MMPs can mediate degradation of tight junction proteins including Occludin, ZO-1 and claudins in epithelial cells. [41] [42] [43] For example, Occludin as well as claudin-5 was reported to be degraded by MMP2 in the blood-brain barrier during ischemia and reperfusion injury. 44, 45 In the present study, changes on Occludin expression could be remarkably abolished by using MMP2/9 inhibitors. Taken together with the data of in vivo MMP2/9 activity, these results suggested that MMP2/9 may play a fundamental role in the degradation of Occludin responding to bacterial attachment to IECs ( Figure 5 ).
In summary, evidence from the present study shows for the first time the role of intestinal P-gp in the disruption of intestinal barrier function under TPN by facilitating bacterial attachment-induced degradation of Occludin. However, in order to further consolidate our hypothesis, more studies using P-gp knockout rats or germ-free rats are needed.
